For decades, the gold standard of medicine was the “average patient.” Clinical trials were designed to find a treatment that worked for the majority and physicians prescribed medications based on those broad statistical successes. But for a significant minority of patients, the “standard of care” was either ineffective or, in some cases, dangerous. This gap in care is where the concept of clinical suitability—or jeok-hap (적합)—becomes the most critical variable in a patient’s recovery.
Clinical suitability is the rigorous process of determining whether a specific medical intervention, drug, or surgical procedure is appropriate for a specific individual based on their unique biological makeup, comorbidities, and lifestyle. It is the bridge between a drug being “FDA-approved” and a drug being “right for you.” As we move deeper into the era of precision medicine, the definition of suitability is shifting from a general checklist of contraindications to a high-resolution map of a patient’s genetic and molecular profile.
The danger of ignoring individual suitability is most evident in pharmacogenomics, the study of how genes affect a person’s response to drugs. For example, a patient may have a genetic variation that makes them a “slow metabolizer” of a specific enzyme. In such cases, a standard dose of a medication could build up to toxic levels in the bloodstream, leading to severe adverse drug reactions (ADRs), which remain one of the leading causes of hospitalization globally.
Moving Beyond the ‘One-Size-Fits-All’ Model
The transition toward personalized suitability is driven by the integration of biomarkers—measurable indicators of a biological state. In oncology, for instance, the suitability of a chemotherapy regimen is no longer determined solely by the location of the tumor (e.g., lung or breast), but by the genetic mutations present within the tumor itself. Testing for biomarkers like HER2 or PD-L1 allows oncologists to determine if a patient is a suitable candidate for targeted therapies or immunotherapies, drastically improving survival rates while sparing unsuitable candidates from unnecessary toxicity.
According to the National Institutes of Health (NIH), precision medicine aims to provide the right treatment to the right patient at the right time. This approach transforms the clinical suitability assessment from a reactive process—where a doctor waits to observe if a drug works—to a proactive one, where the suitability is verified before the first dose is administered.
This shift is not limited to high-cost specialty drugs. Even in primary care, the suitability of common medications, such as statins for cholesterol or antidepressants, is being refined. Factors such as kidney function, liver enzyme activity, and age-related physiological changes are now weighted more heavily to avoid the “prescribing cascade,” where new medications are added simply to treat the side effects of an unsuitable initial drug.
The Framework of Suitability Assessment
Determining clinical suitability requires a multi-layered analysis. It is rarely a binary “yes” or “no,” but rather a calculation of the therapeutic index—the ratio between the dose that produces a toxic effect and the dose that produces a therapeutic effect.
| Feature | Traditional Approach | Precision Approach |
|---|---|---|
| Patient Selection | Based on diagnosis and age | Based on genetic and molecular biomarkers |
| Dosage | Standardized (e.g., 50mg for all) | Weight, metabolism, and genotype-adjusted |
| Risk Analysis | Broad contraindications | Patient-specific risk profiling |
| Goal | Average population benefit | Optimized individual outcome |
The Human Element: Shared Decision-Making
While the science of suitability is increasingly data-driven, the application of that science remains a deeply human interaction. A treatment may be biologically suitable but practically unsuitable. For example, a medication that requires refrigeration and three-times-daily dosing may be biologically a perfect fit, but for a patient with limited transportation or cognitive decline, it is clinically unsuitable due to the high risk of non-compliance.
This represents where shared decision-making (SDM) enters the equation. SDM is a collaborative process that allows patients and providers to make healthcare decisions together, taking into account the evidence about available options and the patient’s preferences and values. As noted by the Mayo Clinic, involving the patient in the suitability conversation increases treatment adherence and improves overall health outcomes.
When a physician asks, “Is this treatment suitable for you?” they are not just asking about your blood perform. They are asking about your quality-of-life goals, your tolerance for side effects, and your ability to maintain the treatment regimen. True suitability is the intersection of biological compatibility and lifestyle feasibility.
Identifying Red Flags in Suitability
Patients can play an active role in monitoring their own suitability for a treatment. While only a licensed provider can determine clinical suitability, patients should be vigilant for “suitability red flags,” including:
- Unexpected Side Effects: Reactions that seem disproportionate to the common side effects listed in the medication guide.
- Lack of Efficacy: A total absence of response to a drug that is typically highly effective for the majority of patients.
- Paradoxical Reactions: When a drug produces the opposite effect of what was intended (e.g., a sedative causing insomnia).
The Role of AI in Predictive Suitability
Looking forward, the most significant leap in determining suitability will come from artificial intelligence and machine learning. AI can analyze vast datasets—including electronic health records, wearable device data, and genomic sequences—to predict suitability with a degree of accuracy that exceeds human capability.
Predictive algorithms are already being used to identify patients who are at high risk for adverse reactions to anesthesia or those who are most likely to respond to a specific type of blood pressure medication. By identifying “non-responders” before treatment begins, the healthcare system can reduce waste and, more importantly, prevent the psychological and physical toll of failed treatments.
But, the integration of AI into suitability assessments brings ethical challenges. There is a risk of “algorithmic bias,” where the data used to train AI is not representative of diverse populations, potentially leading to suitability assessments that are less accurate for minority groups. Ensuring that precision medicine is equitable is the next great challenge for public health officials.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment.
The next major milestone in this field will be the wider implementation of routine pharmacogenomic screening in primary care settings, a move currently being debated by several national health regulators. As these tests develop into more affordable and accessible, the “average patient” will finally become a relic of the past, replaced by a model of care that recognizes the absolute uniqueness of every individual.
Do you believe personalized medicine is the future of healthcare, or are we relying too heavily on data? Share your thoughts in the comments below.
